Thibaut Reverdy
YOU?
Author Swipe
View article: Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study
Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study Open
In patients with recurrent advanced ovarian cancer, there is a need for companion tests to guide the development of innovative chemotherapy‐free treatments. The modeled longitudinal CA‐125 ELIMination rate constant K KELIM‐B was a major pr…
View article: 375P Unmet treatment needs and preferences among metastatic breast cancer (mBC) patients in Germany, Italy, and the United Kingdom
375P Unmet treatment needs and preferences among metastatic breast cancer (mBC) patients in Germany, Italy, and the United Kingdom Open
View article: Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program
Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program Open
Background Healthcare professionals are faced with the new challenges of preventing and managing drug-related problems (DRPs) with oral anticancer therapy (OAT): side-effects, drug–drug interactions (DDIs), non-adherence, or medication err…
View article: 205P Trastuzumab biosimilar (TB) in combination with pertuzumab (P) and chemotherapy (ct) in HER2 positive, metastatic breast cancer (mBC): Efficacy and safety
205P Trastuzumab biosimilar (TB) in combination with pertuzumab (P) and chemotherapy (ct) in HER2 positive, metastatic breast cancer (mBC): Efficacy and safety Open
TB in Europe are available since 2018 and widely prescribed. However, no data have ever been reported regarding their efficacy and tolerance in combination with pertuzumab and chemotherap. Methodology: The observational PErtuzumab – TRAstu…
View article: HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments Open
For several years, the overexpression of the HER2 receptor in breast cancer has been correlated with a poor prognosis and an increased risk of developing brain metastases. Currently, the combination of anti-HER2 double blockade and taxane …
View article: Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives Open
The development of gene expression signatures since the early 2000′s has offered standardized assays to evaluate the prognosis of early breast cancer. Five signatures are currently commercially available and recommended by several internat…
View article: Methods and Designs of Modern Breast Cancer Confirmatory Trials
Methods and Designs of Modern Breast Cancer Confirmatory Trials Open
Background: The benefit–risk assessments of new drugs for breast cancer (BC) face several challenges, as all stakeholders do not agree on the evidence bar required for market authorization, and by the fragmentation of breast cancer diagnos…
View article: Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes Open
It remains unclear whether immune-related adverse events (irAEs) and glucocorticoid use could impact long-term outcomes in patients treated for solid tumors with immune checkpoint inhibitors (ICI). All patients treated with a single-agent …
View article: 1038P Impact of metastatic location on immune-checkpoint inhibitors efficacy in patients with different solid tumours
1038P Impact of metastatic location on immune-checkpoint inhibitors efficacy in patients with different solid tumours Open
View article: Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives Open
Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced sta…
View article: Head and neck cancer and immunotherapy: current knowledge and perspective
Head and neck cancer and immunotherapy: current knowledge and perspective Open
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, h…
View article: Induction chemotherapy in head and neck cancers: Results and controversies
Induction chemotherapy in head and neck cancers: Results and controversies Open
View article: HNSCC and Immunotherapy: The Beginning of a Long Story
HNSCC and Immunotherapy: The Beginning of a Long Story Open
The immunotherapy revolution has not spared Head and neck squamous cell carcinoma (HNSCC).Checkpoint inhibitors (anti-PD-1 / PD-L1) were the first to be validated in second line treatment and soon come to the first line in local or metasta…